Biogen Inc. CEDEAR (BIIB)
BCBA
Closed
Oct 7, 2026
Day's Range
27,520.0052 wk Range
15,000.00Overview - BIIB - Biogen Inc. CEDEAR
Key Statistics
Valuation
Enterprise Value
38,149.80T
P/E (Trailing)
‪3.31‬
PEG Ratio
‪-0.03‬
Price / Sales (TTM)
‪416.98‬
Price / Book
‪0.87‬
EV / EBITDA
‪7,455.82‬
Profitability
Gross Margin
‪71.60%‬
Profit Margin
‪8.32%‬
Operating Margin
‪25.05%‬
Return on Assets
‪5.20%‬
Return on Equity
‪4.57%‬
Ownership
Shares Outstanding
147.70M
Float
881.55M
Held by Insiders
‪0.00%‬
Held by Institutions
‪0.00%‬
Price stats
Beta
‪0.17‬
50-Day Avg
‪26,001.20‬
200-Day Avg
‪22,801.40‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - BIIB - Biogen Inc. CEDEAR
Peers - BIIB - Biogen Inc. CEDEAR
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on BCBA.
Profile Summary - BIIB - Biogen Inc. CEDEAR
About
Biogen Inc. is an American multinational biotechnology company specializing in treatments for neurological diseases and rare conditions. Based in Cambridge, Massachusetts, the company develops and commercializes a diverse portfolio of therapies including LEQEMBI and ADUHELM for Alzheimer's disease, TECFIDERA and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
